Indonesia

Population 2018 268 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>845 (770–923)</td>
<td>316 (288–345)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>21 (8.9–38)</td>
<td>7.9 (3.3–14)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence*</td>
<td>24 (17–32)</td>
<td>8.8 (6.2–12)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>93 (87–99)</td>
<td>35 (33–37)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>5.3 (2.1–9.8)</td>
<td>2 (0.79–3.7)</td>
</tr>
</tbody>
</table>

Estimated TB burden, 2018

- Total TB incidence: 845 (770–923)
- HIV-positive TB incidence: 21 (8.9–38)
- MDR/RR-TB incidence: 24 (17–32)
- HIV-negative TB mortality: 93 (87–99)
- HIV-positive TB mortality: 5.3 (2.1–9.8)

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 2.4% (1.8–3.3)
- Previously treated cases: 13% (9–18)

TB case notifications, 2018

- Total new and relapse: 563 879
- % tested with rapid diagnostics at time of diagnosis: 12%
- % with known HIV status: 37%
- % pulmonary: 88%
- % bacteriologically confirmed**: 50%
- % children aged 0-14 years: 11%
- % women: 37%
- % men: 52%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 67% (61–73)
- TB case notification rate (estimated mortality/estimated incidence), 2018: 12% (10–13)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 33%
- % of patients started on treatment*: 5%
- % of patients continued on treatment*: 40%

Laboratory-confirmed cases: MDR/RR-TB: 9 038, XDR-TB: 80

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 10%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 10% (9.3–11)

TB financing, 2019

- National TB budget (US$ millions): 366
- Funding source: 30% domestic, 13% international, 57% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-12-24 Data: www.who.int/tb/data